quinazolines has been researched along with 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coarfa, C; Edwards, DP; Hilsenbeck, SG; Holdman, XB; Huang, S; Mo, Q; Pond, A; Rajapakshe, K; Rosen, JM; Welte, T; Zhang, X | 1 |
| Cousin, S; Italiano, A; Leroy, L | 1 |
| Borchmann, S; Büttner, R; Dietlein, F; Florin, A; Golfmann, K; Hallek, M; Koker, M; Malchers, F; Meder, L; Rodrik-Outmezguine, V; Rosen, N; Tharun, L; Ullrich, RT; Volz, C | 1 |
| Berger, W; Brankovic, J; Cufer, T; Dome, B; Grasl-Kraupp, B; Grusch, M; Gschwandtner, E; Hegedus, B; Hoda, MA; Kern, I; Klepetko, W; Klikovits, T; Laszlo, V; Mohorcic, K; Peter-Vörösmarty, B; Pirker, C; Rozman, A; Schelch, K; Sinn, K; Vlacic, G | 1 |
| Javle, M; King, G | 1 |
1 review(s) available for quinazolines and 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
| Article | Year |
|---|---|
FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
Topics: Aniline Compounds; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Clinical Trials as Topic; Humans; Morpholines; Mutation; Phenylurea Compounds; Precision Medicine; Pyrazoles; Pyrimidines; Pyrroles; Quinazolines; Quinoxalines; Receptors, Fibroblast Growth Factor; Signal Transduction | 2021 |
4 other study(ies) available for quinazolines and 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
| Article | Year |
|---|---|
Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.
Topics: Animals; Breast Neoplasms; Collagen; ErbB Receptors; Female; Lapatinib; Mammary Neoplasms, Experimental; Mice; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Stromal Cells; Tenascin; Up-Regulation; Wnt1 Protein | 2015 |
Genetic determinants of response to fibroblast growth factor receptor inhibitors in solid tumours.
Topics: Aged; Aniline Compounds; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Mutation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Quinoxalines; Receptors, Fibroblast Growth Factor; Retrospective Studies; Treatment Outcome | 2017 |
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Heterografts; Humans; Mice; Mice, Inbred NOD; Naphthalenes; Neovascularization, Pathologic; Phenylurea Compounds; Piperidines; Pyrimidines; Quinazolines; Quinolines; Receptor, Fibroblast Growth Factor, Type 1; Vascular Endothelial Growth Factor Receptor-1 | 2018 |
Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
Topics: Acrylamides; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Receptor, Fibroblast Growth Factor, Type 4; Survival Analysis | 2019 |